Aisling Capital Management LP Arcus Biosciences, Inc. Transaction History

Aisling Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 10, 2020	SELL	$13.97 - $36.56 $4.66 Million - $12.2 Million	-333,333 Closed	0 $0
Q1 2019 May 20, 2019	SELL	$8.95 - $12.49 $1.82 Million - $2.54 Million	-203,180 Reduced 37.87%	333,333 $4.16 Million
Q4 2018 Feb 08, 2019	BUY	$9.74 - $14.5 $5.23 Million - $7.78 Million	536,513 New	536,513 $5.78 Million

201

48.9M

173K

151K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.19B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Aisling Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Aisling Capital Management LP with notifications on news.